Larazotide: Risks & Legal Status

Critical Safety Information#

Larazotide acetate is an investigational compound whose Phase 3 clinical trial was discontinued in 2022. It is not approved for clinical use in any jurisdiction.

Risk Assessment#

Development Status Risk#

The Phase 3 CeDLara trial discontinuation is the primary concern for larazotide's viability. While the safety profile was consistently favorable, the inability to demonstrate sufficient efficacy in a large Phase 3 trial raises fundamental questions about whether the treatment effect is clinically meaningful in the intended population.

Low Safety Risk#

Despite the efficacy concerns, larazotide's safety profile is noteworthy:

• Adverse events comparable to placebo across all trials
• Minimal systemic absorption limits off-target effects
• No immunosuppressive mechanism
• No serious adverse events attributed to the drug

Misuse Risk#

The association of larazotide with zonulin and "leaky gut" concepts creates a risk of misuse by individuals seeking unproven treatments for non-celiac conditions. Larazotide has only been studied in confirmed celiac disease patients and should not be extrapolated to other conditions without clinical evidence.

Regulatory Status#

Larazotide is not approved in any jurisdiction. Development appears to be halted following the Phase 3 discontinuation.

Risk Mitigation#

For celiac disease patients:

1. Continue strict gluten-free diet as the primary treatment
2. Work with gastroenterologists for symptom management
3. Do not attempt to obtain or self-administer investigational compounds
4. Monitor the celiac disease therapeutic pipeline for emerging approved therapies

Risk Assessment Context#

Larazotide belongs to the Immune category of research peptides. Risk assessment for Larazotide should consider both the compound-specific risks identified in clinical research and the broader regulatory environment. Researchers and healthcare providers should evaluate these risks in the context of the specific patient population and therapeutic indication.

Risk Categories#

The following risk categories have been identified for Larazotide based on available evidence and regulatory assessments:

Development Uncertainty#

The Phase 3 CeDLara trial was discontinued in 2022 after failing to demonstrate sufficient treatment effect. The future development path for larazotide is uncertain.

Investigational Status#

Larazotide is not approved by any regulatory authority. It remains an investigational compound with no established clinical indication.

Limited Efficacy Signal#

While Phase 2b showed significance at 0.5 mg, the Phase 3 failure raises questions about the magnitude and consistency of the therapeutic effect in celiac disease populations.

Regulatory Status by Jurisdiction#

The regulatory and legal status of Larazotide varies by country and jurisdiction. Researchers should verify current regulations before acquiring or using this compound.

Regulatory classifications can change. Researchers are responsible for complying with all applicable laws and regulations in their jurisdiction.

Important Warnings#

The following warnings apply to Larazotide:

• Larazotide is an investigational compound whose Phase 3 trial was discontinued. It is not approved for treatment of celiac disease or any other condition.
• Larazotide does not replace a gluten-free diet. It was designed as an adjunctive therapy for patients already on a gluten-free diet.
• Do not attempt to use larazotide or related peptides as a substitute for medically supervised celiac disease management.

These warnings are based on available preclinical and clinical data. The absence of a warning does not indicate safety. Consult qualified professionals before making any decisions regarding peptide research.

Related Reading#

• Larazotide overview and research guide
• Larazotide side effects profile
• Larazotide research evidence